• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

    1.780 -0.110 (-5.82%)
    Streaming Delayed Price Updated: 10:13 AM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,452
    Open 1.870
    Bid (Size) 1.820 (6,500)
    Ask (Size) 1.880 (100)
    Prev. Close 1.890
    Today's Range 1.780 - 1.870
    52wk Range 1.300 - 3.160
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    These stocks are gapping in today's session ↗
    Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
    From Adagene Inc.
    Via GlobeNewswire

    Performance

    YTD
    N/A
    N/A
    1 Month
    -10.6%
    -10.6%
    3 Month
    -8.2%
    -8.2%
    6 Month
    -3.8%
    -3.8%
    1 Year
    -13.6%
    -13.6%

    More News

    Read More
    News headline image
    Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
    From Adagene Inc.
    Via GlobeNewswire
    Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic ↗
    Via Stocktwits
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene to Participate in Two Investor Conferences in September
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
    Via Benzinga
    News headline image
    Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene announces up to $25 million strategic investment from Sanofi
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene to Present at Jefferies Global Healthcare Conference 2025
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
    From Adagene Inc.
    Via GlobeNewswire
    News headline image
    Adagene to Present at Leerink’s Global Healthcare Conference 2025
    From Adagene Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?
    Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.
    What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?
    Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?
    The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market
    What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?
    The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 1.780
    When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?
    The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 01/02/26 10:13 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.